Readystate Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Readystate Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-117,379	Closed	-$6.1M	–	396
2025 Q3	$6.1M	Sell	117,379 -123,504	-51%	-$6.02M	0.26%	84
2025 Q2	$10.4M	Buy	+240,883	New	+$8.76M	0.32%	65
2025 Q1	–	Sell	-24,582	Closed	-$675K	–	608
2024 Q4	$675K	Buy	+24,582	New	+$635K	0.02%	431

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Readystate Asset Management's BBIO Position: Q4 2025 in Review

Readystate Asset Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 117,379 shares — an estimated $6.1M sold.

Readystate Asset Management first reported a position in BBIO in Q4 2024 and held it in 3 quarters. The position peaked at $10.4M in Q2 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Readystate Asset Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Readystate Asset Management sold 117,379 BridgeBio Pharma shares in Q4 2025, an estimated $6.1M.
Readystate Asset Management first reported a position in BridgeBio Pharma in Q4 2024 and held it in 3 quarters.
Readystate Asset Management's BridgeBio Pharma position peaked at $10.4M in Q2 2025.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.